Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perrigo Mupirocin Cream vs Reference in Secondarily Infected Traumatic Skin Lesions
NCT04155203Phase 3Completed
- Sponsor
- Padagis
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mupirocin in secondarily infected traumatic lesion (SITL), sponsored by Padagis. Started Oct 2019; status: completed.
02
Drugs
mupirocin
03
Conditions
secondarily infected traumatic lesion (SITL)
Beyond the preview
Go deeper on NCT04155203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155203.